GLP-1 Pricing and Regulatory News (September 2026): 25 Dated Stories

Embody (joinem.co): tirzepatide $129 for one month as a sale price against a $349 regular price, $378 for three months, $738 for six, $1,428 for twelve ($119 a month); semaglutide $79 (regular $299), $228, $438, $828 ($69). The refund policy dated August 25, 2026 makes every payment final except on clinical ineligibility, and the “Save $200 instantly” banner carried three names on one day (Fall Sale, Labor Day Promo, Summer Start Promo) with no end date. Four dispensing pharmacies are named — Red Rock Compounding Pharmacy, Health Warehouse, Precision Medicine, Triad Rx — and the prescribers are OpenLoop Health. SnagRx (snagrx.com): $119 tirzepatide against a $399 list price and $69 semaglutide against $299, labelled Labor Day pricing through September 5 and “Fall Sale Discount Applied!” since September 9; the terms (July 27, 2026) limit promotional pricing to the period stated at checkout, after which standard pricing applies; the homepage countdown has read 00:00:00:00 since September 11 with the price unchanged. Month-to-month customers can cancel anytime; all sales are final; Louisiana is excluded. Same pharmacies, same prescriber network, same operator as Embody: Modern Metabolic Medicine, Inc., 1811 Silverside Road, Wilmington, Delaware.

Yucca Health (tryyucca.com): $258 monthly, $744 per three months ($248), $1,350 per six months ($225) with an auto-applied “Exclusive Lifetime Offer” on the six-month rate; flat at every dose; consultation, injection kit and two-day shipping included; no twelve-month plan; all sales final once the prescription is submitted (refund policy August 13, 2026, Brand Merchants Network LLC). Trimi: the plan page prints the whole ladder — $235 monthly, $597 quarterly ($199), $1,050 per six months ($175), $1,500 yearly ($125); semaglutide $175 / $145 / $120 / $99 — and states that payment is taken at checkout before provider review and refunded in full if treatment is not appropriate, and that stopping renewal does not end the current commitment. bmiMD: month-to-month rows verified (tirzepatide “as low as $179” against a $349.20 list price; semaglutide $119 against $228.60), a $50 cancellation fee in the August 24 policy, and a New Year’s banner still on the homepage.

NexLife: the standard cards are unchanged on all five reads ($169 / $159 / $149 / $139 tirzepatide; $139 / $132 / $125 / $119 semaglutide). The tirzepatide plan page states that every plan is “charged monthly as part of subscription” (12-month tile “Save $360”), “Same price at every dose. No memberships or contracts” and “NexLife plans are offered as a subscription and may be canceled at any time”; the plan pages itemise “$377 in added value”, state FSA/HSA eligibility and Klarna/Affirm financing, and carry a money-back warranty tied to losing 10% of body weight in six months. The microdose tirzepatide page leads with “$159 all-inclusive” but its plan tiles still print the prior $189 / $159 / $150 / $147 card, so the microdose rows are now reported rather than verified; the sublingual (ODT) program pages returned 404 on September 4 and 5. Value scores were recomputed against the new field minimums ($1,428 tirzepatide; $828 semaglutide): NexLife 91, SnagRx 90, Trimi 85, Embody 82. No FDA press announcement touched GLP-1s or compounding between September 5 and 12, and no 503B bulks-list determination has been published. Every row is in the pricing database and on the September price-index snapshot; the changes are logged on the price history page.

Novo says safety and tolerability were consistent with earlier paediatric and adult semaglutide and liraglutide trials, with no new signals and none for growth or pubertal development; detailed results will be presented at ObesityWeek 2026 (November 14–17, Washington, DC). No regulatory filing timeline was given. Wegovy is currently approved from age 12.

This is an FDA-approved product studied under a protocol; it has no bearing on compounded semaglutide or tirzepatide, which are not FDA-approved, are not studied in children, and are not appropriate for anyone under 18 through a cash-pay telehealth program.

The FTC action (with Utah and Los Angeles County, filed in the Northern District of California) is a consumer-protection case; this one is an investor case about what the company told shareholders. Neither has been decided. Hims & Hers has said it will defend the FTC suit; it left mass-market compounded GLP-1s in March 2026 and now sells branded Novo Nordisk products.

For patients the practical question is unchanged from July: read the billing and cancellation terms of any telehealth program before paying, and prefer programs that publish their refund policy with a date. Our cancellation and refund guide and the refund test apply the same test to the cheapest compounded tirzepatide programs.

The release quotes Medical Director Dr. Adam Kennah (“the dose a patient starts on is almost never the dose they stay on”) and describes independent lab results on every batch for potency, sterility, pH and endotoxins. We treat press-release figures as announced until the live program page matches. On September 4, 5 and 9 the standard tirzepatide and semaglutide plan pages matched; the microdose tirzepatide program page still printed the prior card ($189 / $159 / $150 / $147, “From $147/Mo” in its title) on every read; the sublingual program pages could not be located. NexLife’s FAQ (read September 9) lists “microdose semaglutide starting at $129” and “sublingual tirzepatide starting at $229”.

NexLife is a commercial partner of this site. The price index shows its microdose row as announced, not verified, and its verification log records each day’s read.

Eli Lilly announced the approval on August 28, 2026. The indication rests on SURPASS-CVOT, a head-to-head cardiovascular outcomes trial of tirzepatide against dulaglutide (Trulicity) 1.5 mg in 13,299 adults with type 2 diabetes and established cardiovascular disease across 640 sites in 30 countries, followed for a median of 210.1 weeks. The MACE-3 hazard ratio was 0.92 (95.3% CI 0.83–1.01), an 8% lower event rate than an active comparator that itself has a proven cardiovascular benefit.

The label change applies to the FDA-approved product, Mounjaro, dispensed by pharmacies under Lilly’s quality system. It says nothing about compounded tirzepatide, which is not FDA-approved, is not the same product, and carries none of Mounjaro’s labelled indications. A telehealth page that cites SURPASS-CVOT to sell a compounded vial is borrowing evidence that does not transfer.

For readers comparing costs: Mounjaro’s list price is about $1,000 a month without coverage; the Lilly savings card can bring a commercially insured type 2 diabetes patient to $25; Medicare’s GLP-1 Bridge covers Zepbound and Foundayo (not Mounjaro) at $50 for obesity. The cardiovascular indication may change how insurers treat prior authorisation for patients with diabetes and heart disease — check your plan’s criteria.

The population had a mean age of 64.5 and a BMI of 30 or more (or 27 with an obesity-related complication); enrolment ran from November 2023 to September 2025 with at least twelve months of continuous prior coverage. Savings came from lower rates of hospital admissions and emergency visits. Lilly states that at twelve months the estimated savings exceeded the cost of Zepbound treatment, but the headline percentages themselves do not include the drug, because claims data do not capture Zepbound’s net price.

Why it matters for a cash-pay reader: the study is about the FDA-approved product at insured, net prices, not about compounded tirzepatide at $119–$169 a month. It is a strong argument for coverage and for the Medicare GLP-1 Bridge’s $50 copay; it says nothing about the safety or effectiveness of a compounded copy.

The complaint says the company charged consumers for prescriptions immediately upon submitting intake forms while telling them a consultation would first decide whether treatment was appropriate; made cancellation difficult (phone, email or chat only at first, then an online button hidden behind multiple steps after 2023); and shared health information through customer lists and tracking technologies despite privacy promises. The FTC’s Bureau of Consumer Protection director described “consumers unknowingly locked into recurring subscriptions and the disclosure to third parties of consumers’ most private health information without their consent.”

Hims & Hers had already announced on March 9, 2026 that it would stop advertising compounded GLP-1s and shift to branded Novo Nordisk products. The FTC case is about subscription mechanics and data, not compounding — which is exactly why it matters to every reader of this site: the same patterns (charge-on-intake, hard cancellation, auto-renewal on multi-month plans, 72-hour notice windows) appear in the terms of the cheapest compounded tirzepatide programs we track.

This site’s reviews now quote each provider’s refund and cancellation policy with its last-updated date. Read the cancellation and refund guide before prepaying any plan.

Reported on July 23, 2026: the two new phase 3 read-outs enrolled patients with either type 2 diabetes or established cardiovascular disease, populations that lose less than the comorbidity-free TRIUMPH-1 cohort. Lilly told CNBC it needed more time to gather manufacturing and quality-control data before filing, which moves a possible approval into 2027 at the earliest.

Retatrutide is not tirzepatide (it adds glucagon-receptor agonism to GIP and GLP-1) and it is not available: it is not FDA-approved, it is not on any shortage list, and there is no lawful compounded version. Any website offering “retatrutide” for weight loss in 2026 is selling an unapproved research chemical.

For patients on compounded tirzepatide, the practical effect is on the timeline: the FDA-approved dual-agonist products (Zepbound, Mounjaro) remain the only tirzepatide products with labelled indications until at least 2027, and the next-generation molecule will launch as a brand at a brand price.

The program runs through December 31, 2027 and is separate from state Medicaid decisions. Eligibility is stricter than the drugs’ labels: BMI 35+, or 27+ with a condition such as heart disease or prediabetes, and enrolment in Part D. Plans process a Bridge prior authorisation; the manufacturers’ commercial savings cards still exclude Medicare and Medicaid beneficiaries by federal rule.

The price context is direct. A Medicare beneficiary who qualifies pays $50 a month for an FDA-approved product with a labelled indication; the cheapest compounded tirzepatide on a provider’s own page is $119 a month (twelve-month prepayment) and the cheapest all-in bundle $139 (see the price index). For eligible Medicare patients the Bridge is the cheaper and the safer route.

Medicare Part D enrollees who do not meet the BMI thresholds are left where everyone else is: manufacturer self-pay ($299–$449 Zepbound vials on LillyDirect; $349 Wegovy pens on NovoCare, $199 for the first two months) or compounded programs that are not FDA-approved.

The agency said a 30-day extension “appropriately balances allowing adequate time for interested persons to submit comments with avoiding significant delay.” The substance is unchanged: FDA proposes that the three molecules do not meet the clinical-need standard for outsourcing-facility bulk compounding, and that affordability is not clinical need.

Until a final determination is published, 503B facilities remain outside the bulks list for these molecules by default (they are not on it and the shortages are over), so the practical position is the same as in April: no lawful pathway for industrial-scale 503B compounding of tirzepatide; patient-specific 503A compounding on a valid prescription continues under state pharmacy law and FDA’s stated scrutiny of “essentially a copy” products.

We will update this page the day a final determination appears. Our 503B explainer: FDA moves to permanently close 503B compounding of tirzepatide.

On May 18, 2026, the FDA issued a warning letter to ProRx, a 503B outsourcing facility, citing its continued production of compounded tirzepatide after the tirzepatide shortage was resolved in late 2024. Under section 503B of the FD&C Act, an outsourcing facility may compound a drug product from bulk drug substances only if the drug is on the FDA's 503B Bulks List or on the active shortage list. Tirzepatide was never on the Bulks List, and the shortage was resolved before the cited compounding activity.

Beyond the bulk-substance citation, the letter documented unsanitary conditions in sterile drug production, labeling deficiencies on several lots, and inadequate adverse-event reporting procedures. The agency required ProRx to cease compounding of the cited drug products and to submit a corrective-action plan within 15 working days.

ProRx reportedly ceased production of the cited products in April 2026, before the formal letter was issued. The cadence of these warning letters has been steady through 2025 and 2026: more than 55 warning letters were issued to online sellers of compounded GLP-1s in September 2025 alone, and additional letters have continued at roughly monthly intervals.

On April 30, 2026, the FDA published a proposed determination that semaglutide, tirzepatide, and liraglutide do not meet the statutory criteria for inclusion on the 503B Bulks List. Under 21 U.S.C. § 353b, an active pharmaceutical ingredient may be compounded in bulk by a 503B outsourcing facility only if it is on the FDA's published Bulks List or on the agency's drug shortage list. With semaglutide removed from the shortage list in February 2025 and tirzepatide removed in December 2024, the only remaining legal pathway for industrial-scale 503B compounding of these molecules was bulks-list inclusion.

The FDA's analysis concludes that there is no current clinical need for outsourcing-facility compounding of these three molecules from bulk API, since FDA-approved products (Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Victoza) are commercially available and meet patient need. The proposal explicitly rejects affordability and insurance access as constituting clinical need within the meaning of the statute.

The proposal does not affect 503A patient-specific compounding by state-licensed pharmacies, which remains legal where each prescription is supported by individualized medical-necessity documentation and the dispensing pharmacy operates under USP <797> sterile-compounding standards. It does, however, foreclose the path that enabled the 30%-of-supply compounding boom of 2024.

On April 1, 2026 the FDA approved orforglipron (brand: Foundayo), Eli Lilly's once-daily small-molecule oral GLP-1 receptor agonist, for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity. Foundayo is the first new-molecule oral GLP-1 FDA-approved for weight management; the previously approved oral GLP-1, Rybelsus (semaglutide), is approved only for type 2 diabetes.

Pivotal evidence comes from the ATTAIN-1 trial program, which compared orforglipron to placebo and to active injectable comparators. Foundayo is not a tirzepatide product and is not a dual GLP-1 / GIP receptor agonist; it is a single GLP-1 receptor agonist administered as a once-daily pill.

The approval changes the market structure of the GLP-1 telehealth segment. Ro signed a deal with Eli Lilly in April 2026 to prescribe Foundayo alongside its existing semaglutide and tirzepatide offerings. Multiple other telehealth providers have signaled plans to add Foundayo to their formularies. The approval does not change the status of compounded tirzepatide, which remains a separate, non-FDA-approved product category.

The finding concerns a combination some compounders market as a differentiator: tirzepatide with added B12 (and sometimes glycine or other additives). Lilly’s position is that the additive reacts with the peptide to form an impurity not present in the FDA-approved product; the compounding industry disputes the generalisation. The FDA had not, as of September 5, 2026, published its own recall order tied to this specific finding, but its February 6, 2026 statement already said it would restrict the ingredients used in mass-marketed compounded GLP-1s.

Several providers in our dataset state that their compounded tirzepatide “may include an additional ingredient such as vitamin B12 or glycine”. An added ingredient does not establish improved efficacy, safety or absorption, and this report is a specific reason to ask which formulation you will receive and to prefer the plain tirzepatide formulation unless a clinician gives you a reason.

Our safety report: adverse events, the B12 impurity and counterfeits.

The announcement followed the FDA’s February 6 statement naming the company, the March 3 wave of 30 warning letters, and Novo Nordisk’s February 9 patent suit over a compounded semaglutide tablet Hims had advertised and then withdrew. The largest direct-to-consumer GLP-1 brand exiting mass-market compounding is the clearest market signal of 2026 that the shortage-era compounding business has ended for national platforms.

It also reshaped the cheapest-price table: Hims and Ro now sell brand products at manufacturer self-pay prices, while the $119–$139 compounded floor is held by smaller telehealth brands (Embody, SnagRx, Trimi, NexLife) whose pages we read daily. Two of those — Embody and SnagRx — are the same company, Modern Metabolic Medicine, Inc. (see the price index).

Pricing for the Novo products through Hims was not disclosed in the announcement; NovoCare’s own self-pay Wegovy price is $349 a month for the pen ($199 for the first two months for new patients through December 31, 2026) and $199–$299 for the pill.

The letters follow the September 16, 2025 wave (55+ letters) and the February 6, 2026 “intent to take action” statement. Commissioner Marty Makary: “It’s a new era of enforcement. We are paying close attention to misleading claims being made by telehealth and pharma companies across all media platforms — and taking swift action. Compounded drugs can be important for overcoming shortages or meeting unique patient needs — but compounders should not try to circumvent FDA’s approval process by mass-marketing compounded drugs.”

The claims the FDA objects to are the ones that appear on many provider pages: “same active ingredient as Zepbound”, “generic Mounjaro”, trial results quoted for a compounded vial. On this site every provider page states that compounded tirzepatide is not FDA-approved and is not the same product as Mounjaro or Zepbound, and the SURMOUNT results are attributed to the FDA-approved injectable only.

Our enforcement timeline: FDA escalates enforcement against GLP-1 telehealth compounders.

In early 2026 the FDA approved an indication expansion for Wegovy (semaglutide) to include metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), supported by data from the ESSENCE trial program. The approval makes Wegovy the second GLP-1 product to gain a non-weight-management indication after Zepbound's December 2024 OSA approval.

The MASH indication is significant because it brings GLP-1 therapy into the liver-disease space at scale. MASH is a leading driver of liver-related morbidity and mortality in U.S. adults, and prior to this approval, treatment options were limited to lifestyle intervention and one recently approved non-GLP-1 product.

The approval does not apply to compounded semaglutide, which remains a separate, non-FDA-approved product category and is not indicated for MASH or any other clinical indication.

TrumpRx does not sell drugs; it lists the manufacturers’ cash programs (LillyDirect, NovoCare) and lets uninsured or self-pay patients compare them with cash pharmacies. The listed prices are dose-dependent and match the December 2025 LillyDirect cut (Zepbound vials $299 / $399 / $449) and Novo’s November 2025 self-pay reset ($349, with a $199 introductory offer). Lilly’s prices “align with its agreement with the Trump administration” under the most-favoured-nation pricing deal.

The same week, Hims & Hers advertised and then withdrew a compounded semaglutide tablet; Novo Nordisk’s February 9 complaint alleged continued mass compounding with “inauthentic API” and comparative safety and efficacy claims against Wegovy. The FDA’s February 6 statement had named Hims specifically.

For price comparison, the brand self-pay floor is now $299 for the lowest Zepbound vial dose and $349 for a Wegovy pen ($199 for the first two months for new patients), versus $119–$169 for compounded tirzepatide programs that are not FDA-approved. The gap is $130–$330 a month, not the $900-plus that list-price comparisons imply.

On February 6, 2026, the FDA issued a press release titled “FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs.” The release laid out the agency's enforcement posture against (1) compounded GLP-1 products that are not the result of individualized prescribing, (2) products containing salt forms of tirzepatide or semaglutide that the agency has not recognized as active pharmaceutical ingredients, and (3) marketing claims that imply equivalence to FDA-approved Mounjaro®, Zepbound®, Ozempic®, or Wegovy®.

The release built on the September 2025 wave of 55+ warning letters to online sellers of compounded GLP-1s and signaled the more structural action that would follow in April with the 503B Bulks-List exclusion proposal. The February release described the harms the agency was addressing: dosing errors from multi-dose vials, adverse-event reports exceeding 455 for compounded semaglutide and 320 for compounded tirzepatide as of early 2025, and counterfeit products entering the market through online channels.

The release was the first public confirmation from the agency that the shortage-era enforcement-discretion window had closed and would not re-open absent a new statutory pathway.

The $449 price for the four higher doses applies on the first fill and on refills made within 45 days of the previous delivery; miss the window and the previous price applies. The 2.5 mg and 5 mg vials carry no refill condition. Novo’s April 2026 price guide sets the Wegovy pen at $349 for every standard dose ($399 for the 7.2 mg HD pen) and the Wegovy pill at $199 (1.5 mg) to $299 (9 mg, 25 mg), with $199 for the first two months for new patients through December 31, 2026.

These are the numbers a compounded tirzepatide price has to beat. At the doses most patients end up on (7.5 mg and above), brand tirzepatide is $449 a month on LillyDirect; the compounded programs in our index run $119 (prepaid) to $169 (month-to-month) and are not FDA-approved. Brand list prices without any program remain about $1,000–$1,350.

This site’s cost pages previously quoted LillyDirect vials “from about $349”; they were corrected to the December 2025 ladder on September 5, 2026.

The warning letter, issued by the FDA's Center for Drug Evaluation and Research (CDER), documented inspection findings from a May 12–15, 2025 inspection (Form FDA 483 issued May 15, 2025) and cited multiple violations of section 503B of the FD&C Act and current Good Manufacturing Practice (cGMP) requirements. Specific cited deficiencies included sterile-production conditions inconsistent with cGMP, multiple drug products lacking essential labeling — active and inactive ingredients, strength, dose, administration instructions — and procedural deficiencies in adverse-event reporting.

An earlier July 2025 recall by a different facility (GenoGenix) covered compounded semaglutide, tirzepatide, retatrutide, and a range of GLP-1 / vitamin combination injectables, on the basis of sterility problems documented during inspection.

Together with the May 2026 ProRx warning letter, these facility-level enforcement actions show that the FDA's enforcement focus is not limited to marketing language but extends to the underlying manufacturing operations of 503B outsourcing facilities producing compounded GLP-1s.

The September 16, 2025 wave of warning letters targeted online sellers of compounded GLP-1 medications for misleading direct-to-consumer advertising in a range of forms: claims of equivalence to brand-name Wegovy® or Zepbound®, claims of FDA approval (which compounded products do not have), claims of “tested,” “verified,” or “FDA-registered” that conflated pharmacy registration with drug approval, and aggressive social-media targeting of patient populations on platforms including Instagram and TikTok.

One representative warning letter, to GLP-1 Solution (715883, 09/09/2025), cited the marketing of retatrutide — an investigational product not approved by the FDA — alongside compounded semaglutide and tirzepatide. The letter described retatrutide as an unapproved new drug and a misbranded drug under sections 505(a), 502(f)(1), 301(a), and 301(d) of the FD&C Act.

The September 2025 wave was framed by commentators at the time as “compliance theater,” and many telehealth providers and compounding pharmacies continued advertising. The follow-up February 2026 “intent to take action” press release and the May 2026 ProRx warning letter together established that the September 2025 letters were not the end of agency action but the beginning.

As of early 2025, the FDA's adverse-event tracking for compounded GLP-1 products had recorded more than 455 reports linked to compounded semaglutide and more than 320 reports linked to compounded tirzepatide. A meaningful share of these reports involved dosing errors from patients drawing incorrect doses from multi-dose vials — in some cases, ten-fold overdoses requiring hospitalization for severe nausea, vomiting, dehydration, or pancreatitis.

The dosing-error pattern is structural rather than incidental. Compounded GLP-1 products are commonly distributed in multi-dose vials with patient-administered syringes, whereas FDA-approved Wegovy, Zepbound, Ozempic, and Mounjaro are distributed in single-dose, fixed-dose pen injectors specifically designed to prevent over-aspiration. The FDA has cited the multi-dose vial format as a recurring contributor to the AE reports.

Counterfeit products entering the U.S. market through online channels have further reinforced the agency's enforcement focus. The agency has expanded import alerts on bulk API not on its recognized “green list” of FDA-inspected manufacturers.

In December 2024 the FDA approved Zepbound (tirzepatide) for adults with moderate-to-severe obstructive sleep apnea and obesity, on the strength of the SURMOUNT-OSA trial program. SURMOUNT-OSA randomized adults with moderate-to-severe OSA and obesity to tirzepatide or placebo for 52 weeks. The trial demonstrated significant reductions in the apnea-hypopnea index (AHI) and in body weight, with a meaningful proportion of patients achieving control of OSA severity criteria.

Zepbound (tirzepatide) is manufactured by Eli Lilly and Company. It was originally approved by the FDA in November 2023 for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity. The December 2024 OSA indication is an expansion of that label.

The OSA indication is clinically significant because it is the first time a drug has been FDA-approved specifically for OSA in adults with obesity — a population for whom CPAP is the standard of care but adherence is often limited.

On October 2, 2024, the FDA published a statement determining that the shortage of tirzepatide injection had been resolved. The agency stated that, after consulting with the manufacturer, present and projected national demand could be met by FDA-approved product supply. Subsequent guidance set enforcement-discretion windows: state-licensed pharmacies (503A) and outsourcing facilities (503B) had defined wind-down periods after which compounding of tirzepatide from bulk substance was no longer permitted on shortage-based grounds.

The semaglutide shortage was separately resolved in February 2025, with similar 503A and 503B wind-down periods.

Between shortage resolution and the April 2026 503B Bulks-List exclusion proposal, the FDA's posture had been one of cumulative escalation: warning letters in September 2025 (55+), the February 2026 “intent to take action” press release, and the May 2026 ProRx warning letter all sit on this timeline.